Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 3/20 | 0.58 |
| ▸ | KIT | P10721 | 2/20 | 0.58 |
| ▸ | BRAF | P15056 | 15/20 | 0.57 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 3/20 | 0.54 |
| ▸ | RAF1 | P04049 | 2/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
| ▸ | ARAF | P10398 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14572598 | 0.93 | LCK (0.57) | CSF1RKITBRAFLCKRAF1 | |
| SCHEMBL14572597 | 0.89 | BRAF (0.55) | KITBRAFKDRRAF1ARAF | |
| SCHEMBL3391195 | 0.89 | BRAF (0.49) | CSF1RKITBRAFPIKFYVELCK | |
| SCHEMBL17537416 | 0.86 | PIKFYVE (0.51) | CSF1RKITBRAFPIKFYVELCK | |
| SCHEMBL4754823 | 0.85 | CSF1R (0.65) | CSF1RKITBRAFPIKFYVELCK | |
| SCHEMBL4718589 | 0.85 | BRAF (0.47) | CSF1RKITBRAFPIKFYVELCK | |
| SCHEMBL3388334 | 0.84 | CSF1R (0.60) | CSF1RKITBRAFLCKKDR | |
| SCHEMBL3387007 | 0.84 | MAP3K7 (0.51) | CSF1RBRAFLCKKDRRAF1 | |
| SCHEMBL3387035 | 0.84 | MAP3K7 (0.59) | CSF1RKITBRAFLCKKDR | |
| SCHEMBL14572593 | 0.83 | BRAF (0.54) | KITBRAFRAF1PDGFRBARAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183248-B2 | Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-05-22 | — | — | US | claimed |
| EP-1891066-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-12-22 | — | — | EP | claimed |
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2009-05-07 | — | — | US | claimed |
| EP-1891066-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-02-27 | — | — | EP | claimed |
| WO-2006124462-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2006-11-23 | — | — | WO | claimed |
| US-8183248-B2 | Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-05-22 | — | — | US | disclosed |
| US-8183248-B2 | Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-05-22 | — | — | US | disclosed |
| US-8183248-B2 | Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-05-22 | — | — | US | disclosed |
| EP-1891066-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-12-22 | — | — | EP | disclosed |
| EP-1891066-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-12-22 | — | — | EP | disclosed |
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2009-05-07 | — | — | US | disclosed |
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2009-05-07 | — | — | US | disclosed |
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2009-05-07 | — | — | US | disclosed |
| EP-1891066-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006124462-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | SRC, FYN, SYK | CSF1R 685/4885KIT 634/4885BRAF 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.